rawfin.tv
MaxCyte Reaffirms 2026 Revenue Outlook of $30M-$32M on Genentech Partnership
EarningsstocksAI Generated

MaxCyte Reaffirms 2026 Revenue Outlook of $30M-$32M on Genentech Partnership

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

MaxCyte has reiterated its 2026 revenue outlook, projecting figures between $30 million and $32 million. This positive reaffirmation is supported by an expanded partnership with Genentech, which is enhancing MaxCyte's enterprise business model.

MaxCyteGenentechBiotechRevenue GuidancePartnerships

Related Articles

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks